Corcept Therapeutics (CORT) is the lead sponsor of 9 active clinical trials listed on ClinicalTrials.gov[4], including 1 Phase 3[1], 6 Phase 2[2], 3 Phase 1[3].
Trial NCT05257408[5] evaluates Nab-paclitaxel 80 mg/m^2 in Ovarian Neoplasm with a target enrollment of 381 participants.
CORT has 8 Form 4 insider filings recorded at the SEC in the past 30 days[6].